Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. PALO ALTO, Calif. — At an annual meeting usually focused on the industry ...

He co-founded a biotech company called Variant Bio that has cut revenue-sharing deals with more than 25 Indigenous groups around the world to use their genomes to discover new targets for drugs.

Scientists have long observed this unusual mode of respiration and harnessed it in biotechnology as something of a black box. Now, a Rice-led team has uncovered its mechanism—a breakthrough that ...

Gift 5 articles to anyone you choose each month when you subscribe. ASX-listed Dimerix has landed one of the biggest licensing deals by an Australian biotechnology company after US pharmaceutical ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

Pliant Therapeutics, a South San Francisco biotech company developing treatments for fibrosis, is slashing its staff after halting a crucial study over safety concerns. This layoff round arrives ...

Buckner was speaking last month at Life Science Innovation Northwest, Seattle’s marquee gathering of the biotech industry. Most years, the two-day conference sees scientists, investors and other ...

Join biotech commentators Daphne Zohar, Josh Schimmer, and Brad Loncar for a weekly discussion of all things biotech. From emerging trends and investment opportunities to the challenges facing the ...

Vertex has elected "not to continue AAV as a delivery mechanism for our genetic therapy programs,” a company spokesperson told Fierce Biotech on Friday. Despite the shift away from AAVs ...

Citing “recent challenges in the capital markets,” Houston said the biotech is rethinking spending to ensure its current cash reserves can take its programs to data milestones. Arvinas is ...

Investors considering a purchase of Krystal Biotech Inc (Symbol: KRYS) stock, but cautious about paying the going market price of $169.11/share, might benefit from considering selling puts among ...